Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MMD ups stake in Nordic Labs

  • News

Executive Summary

Marion Merrell Dow agreed to buy Merieux Canada Holdings Ltd.'s 35.4% stake in the common and preferred stock of the Canadian pharmaceutical firm Nordic Labs, MMD announced April 16. Nordic has been 50%-owned by MMD since 1982, when Nordic began distributing Marion Labs' prescription products in Canada. The purchase will give MMD an 85.4% stake in the company, which it says is the fourth largest pharmaceutical manufacturer in Canada, with 1990 revenues of $ 126 mil. Merieux, when it agreed to acquire Connaught Labs in Setpember 1989, said it would consider selling off Connaught's stake in Nordic.

Table

View full table

Tags:
Latest Headlines

NGGT Progresses First US Gene Therapy Trials For Rare Conditions

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Japan Reimburses Zolbetuximab, To Cut Price Of Imfinzi, Others

Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak

See All
UsernamePublicRestriction

Register

PS019053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By